

## Index

Page numbers in **bold** indicate tables or boxes; page numbers in *italic* indicate figures.

- 21 point checklist, clinical trial
  - assessment 231–3
- a**
- AASD *see* Asian Association for the Study of Diabetes
- abdominal pain 96
- ABI *see* ankle brachial index
- ABPI *see* ankle brachial pressure index
- abscesses, apparent diffusion
  - coefficient 180–1
- accessory ossicle 166
- access to healthcare 25, 37
- acellular wound care products 308
- Achilles tendon lengthening 129, 299, 336, 337, 357, 385–6, 404, 413
- Achilles tendon moment arm, internal 191
- acute painful neuropathies 94–5
- adipose-derived stems cells (ASCs) 441, 443, 444, 449–50
- adipose tissue, injection into plantar
  - foot 413
- administrative staff, diabetic foot clinics 427
- adverse events 231
- aerobic exercise 196, 198
- AFO *see* ankle foot orthoses
- Africa *see* Sub-Saharan Africa
- African Americans, diabetes-related
  - amputation risk 37
- age, DFU risk 109
- Albania 71
- Alexa Diabetes Challenge 217
- alginates, dressings 308
- algorithms 475–512
  - diabetic foot infection 505–12
  - diabetic foot ulcer 479–91
  - hot swollen foot 475–8
  - peripheral arterial disease 493–504
  - reconstructive surgery 461–2
  - vascular assessment 498, 499, 500
- allograft skin 242, 464
- alpha-lipoic acid, neuropathic pain
  - management 100
- alternative medicine 80
- Amazon (company) 217
- American Samoa 87
- amitriptyline 99
- amoxicillin **270**, 274
- ampicillin-sulbactam **270**
- amputation 31–41, 347–64
  - Achilles tendon lengthening 357
  - ankle disarticulation 351, 357, 358–9, 360
  - in Australia 85
  - bone spike projection 158
  - in Brazil 62
  - and Charcot foot 325, 337
  - costs and benefits 21, 24
  - counselling of patients 44–5
  - in Czech Republic 70
  - data collection 432–3

- amputation (*cont'd*)
  - decision to perform 433
  - definition of 32
  - and diabetic foot infection 289, 290
  - direct load transfer 351
  - elective amputation 337
  - end-bearing disarticulation 350
  - epidemiology of 31
  - EQ-5D score 19
  - ethnic differences 35–8, **36**
  - financial costs of 21, 24
  - flap types 354, 357, 358, 360, 361, 362
  - foot amputation, prosthetics 366–8
  - hallux (great toe) amputation 354–5, 379
    - orthotics 367
    - prevention of 380
  - hindfoot amputation 357, 359
  - in Hungary 70
  - incidence of 7, 17, 31, 433
    - global variation 34, **36**
    - study design 32
    - variation within countries 431
  - incisions 358
  - in India 43–4
  - indirect load transfer 352
  - international differences 34, **36**
  - knee disarticulation 350, 351, 361
    - prosthetics 371–2
  - lesser toe amputation 355, 356
  - levels of 350, 354–62
  - limb salvage versus amputation 238–9, 349–50, 377
  - load transfer in 350–2
  - ‘lower extremity amputation’ term 432
  - ‘major LEA’ definition 32
  - metabolic cost of walking with an
    - amputation 348–9
  - midfoot amputation 357, 358
  - minor amputation 17, 24, 32, 146
  - mortality rates 31, 201, 459
  - mortality risk 7–8, 20, 239
  - nerve transection 354
  - in New Zealand 86
  - open wound management 353
  - for osteomyelitis 388
  - outcomes 354
    - in Pakistan 47, 48
    - patient fear of 9
    - patient health status 146
    - phantom-limb pain 353–4
    - plantar pressure elevation 129
    - post-Charcot foot reconstruction 337
    - prevalence of 7, 17
    - prevention strategies 10
    - principles of 365
    - prosthetics 365–76
    - proximal foot amputation 368
    - psychological impact of 347–8
    - quality of life impact 347, 348
    - rates of 24, 34–5
    - ray resection 355–7, 367
    - reconstructive surgery role 468
    - regional differences 34
    - rehabilitation of amputee 365–76
      - impediments to 347–8
    - residual limb pain 354
    - risk assessment study design 32–3
    - risk factors 1, 6–7, 33–8, 43–4
      - ethnic differences 35–8, **36**
      - non-clinical factors 33–8
    - in Romania 68, 69
    - soft tissue envelope 350, 352, 353, 357
    - staged surgery 353
    - in Sub-Saharan Africa 56
    - survival rates 8
    - Syme’s ankle disarticulation amputation
      - 357, 358–9, 360
    - ‘terminal Syme’s amputation’ 354
    - time trends data 34–5
    - tissue management 353–4
    - transfemoral amputation 352, 361–2
      - prosthetics 372
    - transmetatarsal amputation, orthotics 367–8
    - transtibial amputation 299–300, 337, 352, 359–61
      - prosthetics 368–70
    - in UK 105, 261, 479
    - in US 365, 441, 479
    - versus limb salvage 238–9, 349–50, 377
    - weight-bearing in 350–2
  - amyotrophy 95–6
  - anaerobes 269, **270**, **271**, 274

- anastomosis, reconstructive  
microsurgery 467
- anatomic tunnelling, bypass surgery 242
- angiogenesis 446, 449
- angiography 157, 236, 237, 240, 248, 250,  
463, 497, 498
- angioplasty  
endovascular 463  
tibial artery 251, 252, 253–4
- angiosomes, of foot and ankle 293–4, 462
- ankle  
disarticulation 351, 357, 358–9, 360  
realignment arthrodesis 334  
soft tissue oedema 171, 180
- ankle brachial index (ABI) 175, 248, 249,  
290, 296, 329, 494–5
- ankle brachial pressure index (ABPI)  
228, 482
- ankle Doppler signal, PAD diagnosis 495
- ankle foot orthoses (AFO) 357, 367, 368
- ankle-foot prosthetics 371–3
- ankle joint, biomechanics during  
walking 191–2
- annual reviews, for diabetic patients  
112–14
- antibiotic-impregnated cement spacer 390
- antibiotic pellets 160, 161
- antibiotic-resistant bacteria 269, 485–6
- antibiotic treatment 272–4, 291, **477**, 485–7  
comparison of antibiotics 273  
considerations for clinician **509**  
duration of 274, 280–1, 487  
empiric therapy **270–1**, 509  
nurses' role 422  
osteomyelitis 278, 280–1  
outpatient parenteral antibiotic  
therapy 427  
PEDIS Grade 2 (mild) infections 273–4  
PEDIS Grade 3 (moderate) infections 274  
PEDIS Grade 4 (severe) infections 274–5  
selection of 269  
topical treatments 274, 275  
of uninfected ulcers 272  
versus surgical treatment **512**
- anticonvulsants, neuropathic pain  
management 99
- antidepressants, tricyclic, neuropathic pain  
management 99
- antiseptics, wound healing 307
- apparent diffusion coefficient (ADC), MRI  
scans 179–81, 182
- apps  
foot monitoring 205, 210  
wound tracking 215–16
- area under receiver operating characteristic  
curves (AUROC) 2
- arterial lesions 248
- arteriograms 251
- arthrodesis, midfoot realignment 176,  
331–4, 333, 337
- ASCs *see* adipose-derived stems cells
- Asian Association for the Study of Diabetes  
(AASD) 76
- Asians, British *see* Indian Asians, UK
- Association for Podiatry 69
- asymmetrical neuropathies 95–7
- atherosclerosis 247, 248
- athletes, pedal fracture 158
- athletic shoes 131
- audit of foot care *see* clinical audit of  
foot care
- AUROC *see* area under receiver operating  
characteristic curves
- Australia, diabetic foot disease 85–6, 87
- Austria, diabetic foot ulcer, medical costs  
of 9–10
- autolytic debridement 307
- axial screw fixation, CN midfoot 332–3
- aztreonam **271**
- b**
- balance  
centre of mass to centre of pressure  
separation 194–5  
during gait 194–6  
exercise effects 197–8  
impairment  
diabetic neuropathy 109, 144–5  
patient perceptions of 148  
therapeutic footwear 407  
wearable technologies 203–4
- balloon angioplasty 251, 252

- bandaging, compression 304
  - see also* dressings
- Barbados, inpatient beds for diabetic foot disease 260
- barefoot plantar pressure 412
- barefoot walking, plantar ulceration risk 130
- BASIL *see* Bypass versus Angioplasty in Severe Ischemia of the Leg trial
- behavioural factors 139–51
  - DFU development 139–42
  - DFU healing 142–5
  - DFU impact on patient health status 146–7
  - quality of life in DFU patients 147–8
- below knee amputation (BKA) *see* transtibial amputation
- Benin, PAD prevalence **54**
- Bentson wire 250
- bespoke shoes 405, 406
- beta-lactam 274
- bias, amputation incidence study 32
- Biobrane (skin substitute) 464
- biochemistry, DFU diagnosis **481**
- bioengineered products, wound healing 464
- biofilm 276
- bioinformatics analysis 448
- biomechanics 125–37
  - barefoot walking 130
  - effective mechanical advantage 191, 192
  - fall risk 193
  - of gait 188–92
  - ground reaction force 191
  - muscle atrophy 129
  - plantar pressure elevation and foot ulceration 126–8
  - prevention of DFU 132–3
  - treatment of DFU 130–2
- biothesiometers 44
- bivalved total contact casts 131
- BKA (below knee amputation) *see* transtibial amputation
- BM *see* bone marrow
- BM-MPCs *see* bone marrow-derived mesenchymal progenitor cells
- bone biopsy 278, 316–17
- bone demineralization 160, 161
- bone erosions 165
- bone marrow (BM), neovascularization 446
- bone marrow-derived mesenchymal progenitor cells (BM-MPCs) 445, 447
- bone marrow-derived stem cells 451
- bone marrow oedema 172, 174
  - MRI scans 180, 182
- bone necrosis 353
- bone resorption 164, 316–17
- bone scans 180, 182, 277
- bone specimens, cultures of 269
- bone spike, post-amputation 158
- bony prominences
  - normal anatomy 165, 166
  - plantar pressure elevation 125–6, 127
- Brand, Paul 111, 126
- Brazil 61–5
  - Brazupa Study 62, 63
  - costs of diabetic foot disease/treatment 9, 261
  - Step by Step training courses 64
- breast cancer 18, 19
- Brodsky Anatomic Classification of Charcot arthropathy 327
- Bulgaria 71
- bunion (hallux valgus) 92, 111, 355, 356
- Burgess, Ernest 347
- Burkina Faso **55**
- bypass surgery 235–45, 275, 463
  - benefit/risk assessment 237–9
  - communication with patient 239
  - distal ‘target’ vessels 239–40
  - effectiveness of 237
  - with endovascular revascularization 252, 254
- endovascular revascularization
  - comparison 253
- follow-up after operation 243
- frail, marginal patients 238–9
- graft tunnelling 242
- in-hospital recovery 242–3
- mortality rate 237
- operation procedure 241–2

- PAD identification in diabetes patients 235–7
- patients with no limb function 238
- rehabilitation potential 238
- risk/benefit assessment 237–9
- surgeon communication with patient 239
- ‘target’ vessels 239–40
- technique 241–2
- vascular anatomy evaluation 239–41
- venous conduit 240–2
- wound healing 242, 243
- Bypass versus Angioplasty in Severe Ischemia of the Leg (BASIL) trial 253, 254
- C**
- cadaver skin (allograft) 242, 464
- CAD-CAM *see* computer-aided manufacturing system
- calcanectomy 298, 391
- calcaneum, ‘open beak’ fracture 158–60
- calcification, vascular 157, 162
- calcitonin gene-related peptide (CGRP) 315
- calluses, ulceration risk 111, 119, 127, 128
- CAM *see* complementary or alternative medicine
- Cameroon
- health outcomes for diabetes population 55
- PAD prevalence 54
- peripheral neuropathy prevalence 53
- carbapenem 271, 274
- care pathways 25, 435, 436, 488–9
- care principles 420
- care quality 23
- care standards 230
- Caribbean, amputation incidence 37–8
- carpal tunnel release 97
- case reports/series 226
- cast walkers 130, 131, 145, 214, 319, 320, 336, 385–6, 485
- cautery 80
- CCGs *see* Clinical Commissioning Groups
- cDNA *see* complementary DNA
- CDUS *see* colour Doppler ultrasound
- cefepime 271
- cefotaxime 270
- ceftazidime 271
- ceftriaxone 270
- cell phones 215
- see also* smartphones
- cellulitis 319
- cellulitic foot 475, 476–7
- cement spacer, antibiotic-impregnated 390
- CE-MRA *see* contrast-enhanced magnetic resonance angiography
- central nervous system (CNS), diabetic neuropathy 97–8
- central ray resection 356–7
- cephalexin 270
- cephalosporin 273
- CGRP *see* calcitonin gene-related peptide
- Charcot fractures, plantar pressure elevation 128–9
- Charcot neuroarthropathy (CN) (Charcot foot) 139, 170, 313–23, 419–20
- Achilles tendon lengthening 336, 337
- acute management of 318–20
- amputation risk 325
- bone marrow oedema 172, 174, 177
- bone resorption and inflammation link 316–17
- Brodsky Anatomic Classification 327
- clinical impact of neuropathy on bone 314
- clinical presentation 318–19
- diagnosis 319
- foot deformity 318, 326, 327, 328
- footwear 406
- fractures, plantar pressure elevation 128–9
- gastrocnemius recession 299, 336
- genetic factors 317–18
- glycaemic control 329–30
- histological analysis, bone specimens 316–17
- inflammatory response to trauma 315–16
- investigations and diagnosis 319
- midfoot breakdown 333
- midfoot deformities 327, 328
- MRI scans 174, 177, 177, 178, 179

- Charcot neuroarthropathy (CN) (Charcot foot) (*cont'd*)
- negative cuboid height 328
  - neuropeptides 315
  - nonplantigrade deformity 326
  - non-surgical interventions 176
  - offloading treatment 319–20
  - osteoclast activation 316
  - pathogenesis of 313–18
    - theories 313–14
  - patient health status 146
  - pharmacological therapies 320
  - plantar ulceration 326
  - post-operative management 336
  - preoperative medical workup 329
  - prevalence of in diabetic patients 325
  - radiographs 156, 157, 162–4, 172, 173, 174, 319, 326, 327–8
  - renal disease/impairment 330
  - Sanders and Frykberg Anatomic Classification 327
  - serial radiography 156, 157
  - surgical reconstruction 176, 325–46, 413
    - Achilles tendon lengthening 336, 337
    - amputation rate 337
    - ancillary procedures 336
    - exostectomy 330–1, 337
    - fixation methods 337–8
    - glycaemic control assessment 329–30
    - hindfoot and ankle 334
    - indications for 325–6
    - internal/external fixation 334–6, 337–8
    - midfoot deformity correction 326, 331–3
    - outcomes 330–7
    - PAD assessment 329
    - post-operative management 336
    - procedures 330–6
    - realignment arthrodesis 331–4, 333, 337
    - recommendations 337–8
    - renal function 330
    - timing of surgery 328–9, 337
    - Vitamin D deficiency 330
  - talonavicular and subtalar dislocation 326
  - trauma response 315–16
    - treatment 319–20
    - unilateral foot swelling 318
    - Vitamin D deficiency 330
    - see also* diabetic neuropathy
- Charcot restraint orthotic walker (CROW) 391
- checklists, clinical trial assessment 231–3
- China 75
- chiroprodists 81
- chronic limb-threatening ischemia (CLTI) 235, 237, 238
- chronic obstructive pulmonary disease (COPD) 18, 19
- chronic wounds, healing therapies 308–9
- ciprofloxacin 271
- claw toes 92, 119, 128, 413
- cleaning of wound *see* debridement
- clerical staff, diabetic foot clinics 427
- CLI *see* critical limb ischemia
- clindamycin 270, 273, 274, 280
- clinical audit of foot care 431–40
  - new ulceration onset 435
  - outcome measures 432–4
  - populations, definition of 434
  - principles of 432–5
  - purpose of 431–2
  - wound healing 434–5
- Clinical Commissioning Groups (CCGs) 24, 436
- clinical outcomes *see* health outcomes
- clinical trials, assessment of 225–34
  - 21 point checklist 231–3
    - adverse events 231
    - diabetic person, features of 228
    - foot, features of 228
    - guidelines 225–6
    - hierarchy of evidence 226–7
    - intervention/therapy description 230
    - limb, features of 228
    - limb outcomes 231
    - person outcomes 230
    - population factors 227–8
    - scoring systems 225
    - ulcer, features of 229
    - ulcer-related outcomes 231

- clinics *see* diabetic foot clinics
- clopidogrel 250
- CLTI *see* chronic limb-threatening ischemia
- cluster analyses 142
- CN *see* Charcot neuroarthropathy
- CNS *see* central nervous system
- coamoxiclav 486
- Cochrane reviews
- antibiotic therapy for DFI 273
  - patient education 487
- cognitive impairment 487
- collagenases, topical, wound cleaning 307
- collagen bilayer matrix, wound closure 297
- colloid imaging 177
- colour Doppler ultrasound (CDUS) 496–7
- Common Sense Model (CSM), illness
- behaviour 141, 142
- communication with patient, surgeons 239
- comorbidities, DFU management 487
- complementary or alternative medicine (CAM) 80
- complementary DNA (cDNA) 448
- computed tomography (CT) 153–4, 175–7
- advantages/disadvantages of 175–6
  - multidetector-row computed tomography angiography 497
  - osteomyelitis 176
  - single photon emission computed tomography 172–3
- computer-aided manufacturing (CAD-CAM) system 367
- computerized radiography (CR) 154, 155
- contrast-enhanced magnetic resonance angiography (CE-MRA) 498
- COPD *see* chronic obstructive pulmonary disease
- cost-effectiveness
- DFU and amputation prevention 10
  - EQ-5D instrument 19
  - healthcare interventions 23–5
  - limitations of 24–5
- costs of diabetic foot disease/treatment
- 9–10, 22, 24, 106, 303, 479
  - in Brazil 62, 261
  - global cost 201, 202
  - in India 43
  - in UK 17–29, 225
  - in US 170, 225
  - see also* delayed presentations
- Cote d'Ivoire *see* Ivory Coast
- counselling 44–5, 354, 414–15
- country/region perspectives
- Australasia 85–8
  - Brazil 9, 61–5
  - China 75
  - Eastern Europe 67–73
  - India 43–5, 57
  - Middle East 79–83
  - Pacific region 75–7, 86–7
  - Pakistan 47–9
  - Romania 67–9
  - see also* Sub-Saharan Africa; United Kingdom; United States
- CR *see* computerized radiography
- cranial nerve palsies 96
- creams, moisturizing 81
- critical limb ischemia (CLI) 237, 482
- CROW *see* Charcot restraint orthotic walker
- CSM *see* Common Sense Model
- CT *see* computed tomography
- cuff suspension 370
- cultural values 80
- cushioning, footwear 399
- custom-made footwear 133, 405, 406
- cysts, fsT2W imaging 179
- cytokines 316
- Czech Republic 70
- d**
- daptomycin 271
- DARTS study (Diabetes Audit and Research in Tayside Scotland) 106
- data collection
- on amputation 432–3
  - DFUs in England and Wales 436–7
  - information reliability 433
  - for National Diabetes Foot Care Audit of England and Wales 435
  - principle of 434
- DDR *see* direct digital radiography

- death *see* mortality
- debridement 294, 295, 296, 297, 306–7, 462–3
- larval debridement 275, 280, 307, 483
- deformities *see* foot deformities
- delayed presentations 52, 68
- ‘dental’ imaging plates 154–5
- depression
- and amputation 348
  - and DFU healing 142–3
  - DFU incidence and 140–1
  - and DFU risk 147–8
  - predictors of 144–5
- dermal substitutes *see* skin grafts/substitutes
- dermatological examination 290
- dermatologists 424
- developing countries
- diabetes in 43
  - diagnosis of high risk feet 44
  - see also individual countries*
- DFA *see* Diabetic Foot Australia
- DFCAs *see* diabetic foot care assistants
- DFD *see* diabetic foot disease
- DFI *see* diabetic foot infection
- DFO (diabetic foot osteomyelitis) *see* osteomyelitis
- DFS *see* Diabetic Foot Ulcer Scale
- DFU *see* diabetic foot ulcer
- Diabetes Audit and Research in Tayside Scotland (DARTS) study 106
- diabetes mellitus (DM)
- diagnosis miscoding 32
  - duration of, and DFU risk 109
  - incidence/prevalence 32, 47, 433
    - global 31, 201, 202
    - in US 169, 441
  - infection pathophysiology in diabetic persons 265–6
  - with macrovascular complications, EQ-5D score 19
  - risk factors 169
  - type 1 and type 2 differentiation issue 32
  - under-reporting of 32
- Diabetes UK 261
- Diabetic Foot Australia (DFA) 86
- diabetic foot care assistants (DFCAs) 47
- diabetic foot clinics 204, 419–29
- administrative staff 427
  - care principles 420
  - dermatologists 424
  - DFU investigations **481**
  - diabetologists 422
  - emergency patients 425
  - in-patient care 427
  - interventional radiologists 423
  - joint specialist clinics 425–6, 427
  - leadership 428
  - location of 420
  - microbiologists 423–4
  - multidisciplinary teams 425–6
  - multidisciplinary vascular radiology meetings 426–7
  - nurses 422
  - occupational therapists 424
  - open access service 425
  - organisation of 424–8
  - orthopaedic clinics 426
  - orthopaedic surgeons 423
  - orthotists 422
  - outpatient parenteral antibiotic therapy 427
  - personnel for 421–4
  - pharmacists 424
  - physiotherapists 424
  - plastic clinics 427
  - plastic surgeons 423
  - podiatrists 421–2
  - psychiatrists 424
  - radiologists 423
  - reception staff 427
  - space for 420–1
  - vascular clinics 426
  - vascular scientists 423
  - vascular surgeons 423
- diabetic foot disease (DFD)
- burden of inpatient DFD 260–1
  - in Middle East 79–80
  - natural history of 419–20
  - pathophysiology of 170
  - risk assessment **93**
  - surgery for 377–95



- diabetic foot infection (DFI) 265–87  
 algorithms 505–12  
 amputation risk 289, 290  
 antibiotic treatment 269, **270–1**, 272–4, 291, **509**  
 classification of **267**, 268, 291, 505, **507**  
 clinical signs and symptoms 266–8  
 clinical trial assessment 229  
 dermatological examination 290  
 diagnosis 266, **267**, 505, 506, **507**  
 examination 290–1  
 hospitalization requirement **508**  
 hyperbaric oxygen therapy 275  
 IDSA classification **507**  
 incidence of 265  
 infection pathophysiology 265–6  
 infectious disease consultation 296  
 and kidney function 44  
 microbiological analysis 268–72  
 musculoskeletal examination 290–1  
 neurological examination 290  
 offloading treatment 298  
 PEDIS classification **267**, **507**  
 plastic surgery consultation 296  
 quality of life impact 289  
 radiographic evaluation 291  
 revascularization 275  
 risk factors 266  
 severity of **508**  
 soft tissue/tendon balancing 299  
 in Sub-Saharan Africa 55–6  
 surgery 289–302  
   debridement 294, 295, 296, 297  
   infection tracking 294  
   initial intervention 292  
   irrigation 295  
   offloading treatment 298  
   osseous reconstruction 298–9  
   proximal level amputation decision 299–300  
   tissue viability, colour guide 294  
   vascular surgery consultation 295–6  
   wound closure techniques 296–8  
 symptoms 266–8  
 treatment 507–12  
   vascular examination 290  
   white blood cell count 176, 177  
   *see also* osteomyelitis
- Diabetic Foot International 439
- diabetic foot osteomyelitis (DFO) *see* osteomyelitis
- diabetic foot ulcer (DFU) 479–91  
 age of patient 109  
 area and depth 229  
 assessment 480–2, **484**  
 in Australasia 87  
 behavioural factors 139–51  
 biomechanics 125–37  
 in Brazil 61, 62  
 causation 116, 117  
 Charcot foot 326  
 classification of 2–3, 6, 9–10, 434, 482  
 clinical care 480–3  
 clinical trial assessment 229  
 comorbidities management 487  
 component cause 116, 117  
 definition of 1–2  
 and depression 140–1, 142–5  
 and diabetes duration 109  
 and diabetic neuropathy 107–9  
 dressings 303–11  
 duration of at first assessment 436, 437  
 economic impact 9–10  
 emotional factors 147  
 epidemiology 1–9  
 EQ-5D score 19  
 ethnic differences 35, 110  
 financial cost 9–10, 25, 62, 303  
 footwear reviews 482  
 healing of 2, 6, 132, 142–3, 145, 303, **305**  
 health centred outcomes 7–8  
 hemorrhagic callus, examination for 414  
 hospitalization 4, 5, 7  
 imaging studies 180, **481**, 482–3  
 incidence of 3–5, 17–18, 25, 61, 201, 479  
 infection identification 480–1  
 initial assessment **484**  
 ischemic DFU 481  
 location for ulcer 2–3

- diabetic foot ulcer (DFU) (*cont'd*)
- management of 215–17, 483–9
    - clinical care 480–3
    - dressings 303–11
    - effectiveness measurement 431–40
    - overview 486
    - structural care process 488–9
  - mechanical factors 118–20, 484–5
  - medical cost 9–10, 25, 62, 303
  - metabolic control 487
  - microbiological control 485–7
  - microvascular complications 110
  - mortality risk 7–8, 20, 479
  - MRI scans 180
  - multidisciplinary treatment 10
  - neuroischemic ulcers 419, 463, 482
  - neuropathic ulcers 463
  - in New Zealand 86
  - non-healing ulcers 449
  - outcomes 7–9
  - and PAD 106–7
  - pathogenesis 105–11
  - pathophysiology 52
  - pathways to 107, 116–17
  - patient assessment 480
  - patient centred outcomes 8–9
  - patient health status impact 146–7
  - patient perceptions of 141–2
  - PEDIS classification 267, 268
  - plantar pressure elevation 126–8
  - presentation delays 419
  - presentations of 481–2
  - pressure ulcers 119–20
  - prevalence of 3–5, 17–18
  - prevention of 10, 57–8, 132–3, 214–15, 378, 414–15
  - previous foot ulceration 110
  - psychological factors 139–51
  - quality of life impact 146–8
  - re-admission to hospital 7
  - recurrence of 5, 6, 133, 204, 378, 411, 435
  - referral pathway 488–9
  - risk assessment 93, 111–15
  - risk factors 6–7, 35, 106–11, 133, 147–8
  - risk reduction 217–18
  - in Romania 68
  - sampling techniques 480–1
  - self-care practices 6
  - severity of ulcer at first assessment 437
  - sex of patient 109
  - smart technology 202, 204–11
  - socio-economic impact of 146
  - in Sub-Saharan Africa 51, 52, 54–5
  - sufficient cause 116, 117
  - and trauma 106
  - treatment of 130–2
  - types of wound 463
  - ulcer aetiology 2
  - in US 441, 459
  - vascular control 483–4
  - warning signs 414
  - wound classification 2–3, 6, 9–10, 235, 236, 238, 243, 268, 291, 434
  - wound number/location 443
  - see also* diabetic foot infection; wound care/healing
- Diabetic Foot Ulcer Scale (DFS)
- questionnaire 147
- diabetic neuropathy (DN) 89–103, 110, 170
- acute painful neuropathies 94–5
  - asymmetrical neuropathies 95–7
  - balance during gait 194–6
  - bone impact 314
  - central nervous system involvement in 97–8
  - chronic neuropathy 108
  - chronic stable neuropathic foot 164
  - classification of 89–90
  - clinical trial assessment 228–9
  - and depression 140, 144
  - and DFU pathogenesis 107–9
  - diagnosis 69, 92, 93, 94
  - distal symmetrical neuropathy 90, 91–3, 97–8
  - epidemiology 89
  - fall risk 193
  - fracture pattern 163
  - gait 130, 187–200
  - Indian Asians, UK 38
  - management of 98–101

- MRI scans 189  
 muscle atrophy 129, 188  
 Neuropathy Disability Score **113**  
 Norfolk QoL-Diabetic Neuropathy Scale 68  
 offloading adherence 143–4  
 pain 91, 94–5  
     treatment of 98–101  
 pathogenesis 97–8  
 peripheral sympathetic autonomic neuropathy 108–9  
 prevention of 98  
 quality of life analysis 68  
 sensory loss 108, 120  
 in Sub-Saharan Africa 52–3  
 symmetrical neuropathies 91–5  
 unsteadiness symptom 109, 144–5, 195–6  
     *see also* Charcot neuroarthropathy  
 diabetic truncal radiculopathy (DTR) **90**, 96  
 diabetologists 422  
 diagnostic codes, ICD-9 4  
 dialysis treatment, DFU risk 110  
 dicloxacillin **270**  
 diffusion tensor imaging (DTI) 181  
 diffusion weighted imaging (DWI) 179, 180, 181, 182  
 digital subtraction angiography (DSA) 497, 498  
 digital technologies  
     DFU management 215–17  
     foot monitoring 205  
 ‘digital wellness’ 216  
 direct digital radiography (DDR) 154, 155  
 disease models 111, 141  
 dislocations, Charcot foot 326  
     *see also* fractures  
 distal sensory peripheral neuropathy (DSPN) 145  
 distal symmetrical neuropathy **90**, 91–3, **94**, 97–8  
 Dixon-based MR techniques 178–9  
 DM *see* diabetes mellitus  
 DN *see* diabetic neuropathy  
 Doppler audible signals, PAD diagnosis 495  
 Doppler imaging 175  
 dorsal foot temperature **113**, 114  
 dorsalis pedis artery, reconstitution of 240  
 doxycycline **270**, 274  
 dressings 303–11, 365  
     compression bandaging 304  
     cost of 303  
     definition of 304–5  
     evidence requirement/quality 304  
     matrix metalloproteinases modulation 309  
     problems 303–4  
     wound healing 306–8  
 DSA *see* digital subtraction angiography  
 DSPN *see* distal sensory peripheral neuropathy  
 DTI *see* diffusion tensor imaging  
 DTR *see* diabetic truncal radiculopathy  
 duloxetine 99  
 Duplex ultrasonography 423, 496–7  
 DWI *see* diffusion weighted imaging  
 dynamic response feet 371  
 ‘dynamic sway’ 195, 196  
 dynamometers 188–9
- e**
- East Asia 75  
 Eastern Europe 67–73  
 economic factors 9–10, 202  
 education programmes *see* patient education  
 effective mechanical advantage (EMA) 191, 192  
 Egypt  
     complementary medicine 80  
     DFU recurrence 5  
     diabetic foot disease prevalence **79**, 80  
 elastomer orthosis 367  
 electrical spinal cord stimulation 100  
 electrical stimulation, plantar 217–18  
 electronic diagnostic codes (ICD-9) 4  
 electrophysiology **112**, 114  
 elevation test 319  
 EMA *see* effective mechanical advantage  
 embryonic stem cells (ES) 444, 447  
 emergency patients 425, 489

- emotional factors
    - patient distress 147
    - and self-care behaviours 141, 142
  - endothelial progenitor cells (EPCs) 446
  - endovascular revascularization 238, 250–5, 275, 463
    - advantages of 252
    - bypass surgery comparison 253
    - combined with bypass surgery 252, 254
    - complications 254
    - prior to bypass surgery 254
    - results 253–4
    - risks of 254
    - technique 250–2
  - end-stage renal disease (ESRD) 330
  - energy-storing-and-returning feet (ESR) 371
  - England
    - costs of diabetic foot disease/treatment 17–29
    - DFU incidence 17–18
    - diabetic foot care, guidelines 23
    - diabetic-related amputation 105
    - inpatient beds for diabetic foot disease 260
    - National Diabetes Foot Care Audit 25, 303, 435–9
    - see also* Scotland; United Kingdom
  - enterobacteriaceae **270, 271**
  - entrapment neuropathy 97
  - EPCs *see* endothelial progenitor cells
  - EQ-5D instrument 19
  - equinus contractures 336
  - ertapenem **270**
  - erythema **267**
  - erythrocyte sedimentation rate (ESR) 276, 483
  - ES *see* embryonic stem cells
  - ESF *see* Estratégia de Saúde da Família
  - ESR *see* energy-storing-and-returning feet; erythrocyte sedimentation rate
  - ESRD *see* end-stage renal disease
  - Estratégia de Saúde da Família (ESF) 61
  - Ethiopia
    - health outcomes for diabetes population **55**
    - PAD prevalence **54**
    - peripheral neuropathy prevalence **53**
  - ethnicity
    - and amputation risk 35–8, **36**
    - and DFU risk 110
  - EURODIAB Prospective Complications Study 89
  - Eurodiale Study 1, 2, 7, 20, 62, 146
  - European Wound Management Association (EWMA) 226
  - Europe, diabetes incidence 67
    - see also* Eastern Europe; *individual countries*
  - evidence hierarchy, clinical trial assessment 226–7
  - examination of foot *see* foot examination
  - exercise
    - and DFU healing 145
    - and DFU risk 148
    - and diabetic neuropathy 196–8
    - harmful activities 213
    - levels of 213
    - management of 211–14
    - recommendations for diabetes persons 211–14
    - resistance exercise training 196–7, 198
    - and smart technology 211–14
    - weight-bearing exercise 196, 197
  - exostectomy 330–1, 337
  - external moment arm length (ExtMA) 191
- f**
- FAAM *see* Foot and Ankle Ability Measurement
  - FACS *see* fluorescence-activated cell sorting
  - falls, risk of 193
  - fatalistic attitudes, patients 80
  - fat-saturated T2-weighted (fsT2W) imaging 178, 179, 181
  - FBG *see* Fibre Bragg Grating
  - FED *see* Footwear for Every Diabetic
  - ‘Feet at Risk’ clinics 48
  - femoral neuropathy 95–6
  - Fibre Bragg Grating (FBG) 205
  - FIELD Study 33

- fifth metatarsal head resection 384, 385
- Fiji 86, 87
- financial costs *see* costs of diabetic foot disease/treatment
- fixation methods, CN midfoot 332–6, 337–8
- flaps
  - amputation surgery 354, 357, 358, 360, 361, 362
  - reconstructive surgery 463, 465–8, 469, 470
- Flex Foot 371
- flexor tendon tenotomy 132, 133
- flucloxacillin **270**
- fluorescence-activated cell sorting (FACS) 448
- fluoroquinolone 274, 280
- fluroscopy 251
- foam cushioning, footwear 399
- focal peripheral neuropathies 96
- folk medicine 80
- Foot and Ankle Ability Measurement (FAAM) 289–90
- foot care education *see* patient education
- foot clinics *see* diabetic foot clinics
- foot compartments 292, 293
- foot deformities
  - Charcot foot 318, 326, 327, 328, 331–3
  - claw toes 92, 119, 128, 413
  - DFU risk 111
  - effects of 178
  - hammertoes 413
  - plantar pressure elevation 128
  - radiography 158
  - ‘rocker bottom’ foot 128–9, 330–1
- foot drop 97
- foot examination 112–13, 261–2, 290–1
- foot infection *see* diabetic foot infection
- foot pressure measurement *see* plantar pressure measurement
- foot protection clinics/services 10, 489
  - see also* diabetic foot clinics
- foot temperature *see* plantar temperature measurement/monitoring
- foot ulcers *see* diabetic foot ulcer
- footwear 81, 92, 130–3, 336, 397–410, 482, 484–5
  - adherence to therapeutic footwear 213, 215, 406–7
  - and balance impairment 407
  - bespoke shoes 405, 406
  - ‘breaking-in’ shoes 405–6
  - choosing for patients with LOPS 405–7
  - custom-made footwear 133, 405, 406
  - DFU causation/risk 118, 130
  - for diabetic patient with recently healed ulcer 406
  - for diabetic patient with ulcer 406
  - foam cushioning 399
  - footwear pyramid 406
  - in-shoe plantar pressure 126, 402–3
  - insoles 132, 210, 211, 212–13, 215, 355, 399, 400, 402, 415
  - laces 398
  - load transfer 400
  - metatarsal pads and bars 400, 402
  - need for therapeutic shoes 404
  - offloading
    - by plantar area at risk 403–4
    - by plantar pressure measurement 401–3
  - orthoses 399–400
  - patient perceptions of 142
  - plantar pressure measurement 401–3, 405
  - plantar temperature monitoring 207–10
  - prevention of plantar ulcers 132
  - remission maintenance 412
  - rigid shoes 400–1
  - rocker shoes 131, 368, 400, 401
  - roller shoes 400, 401
  - shoe ‘break-in’ 405–6
  - shoe uppers 398
  - slip-on shoes 398
  - smart footwear 212–14
  - smart socks 205, 207–10
  - smart technology 203–4
  - temperature and humidity monitoring 210
  - total contact casts 130, 131, 145, 214, 319, 320, 385–6, 485
  - velcro closure 398
  - versus surgery 404
  - see also* gait

Footwear for Every Diabetic (FED) 48  
 footwear technicians 48  
 forefoot osteomyelitis, surgery 388–90  
 foreign bodies, radiography 174  
 fractures  
   Lisfranc fracture 163, 171  
   radiography 156, 157, 158–60  
   *see also* dislocations  
 free flaps, reconstructive surgery 466–8, 469  
 Fremantle Diabetes Study 33  
 fsT2W (fat-saturated T2-weighted)  
   imaging 178, 179, 181

## g

gabapentin 99, 100  
 gadolinium contrast, MRI scans 179, 498  
 gait 144, 145, 187–200  
   ankle joint during walking 191–2  
   and balance 194–6  
   biomechanics of 188–92  
   characteristics of diabetes persons 187–8  
   diabetic neuropathy 130  
   exercise effects 197–8  
   fall risk 193  
   ‘hip strategy’ 192  
   improvement strategies 190–2  
   measurement of 204–5  
   metabolic cost of amputation 348–9  
   metabolic cost of walking 192  
   muscle forces 188–90  
   stair-walking 195  
   step width 195–6  
   unsteadiness during walking 195–6  
   walking speed 191, 192, 348  
   wearable technologies 203–4  
   weight-bearing function of foot 348  
   *see also* footwear  
 gangrene 55, 56, 68, 157  
 gases, topical, wound healing 308  
 gas, in soft tissues 162, 291, 294  
 gastrocnemius recession 299, 336, 386  
 G-CSF *see* granulocyte colony stimulating factor  
 GDP *see* gross domestic product  
 gene expression analyses 448–9, 450

genetic factors, Charcot foot 317–18  
 geriatric depression, and DFU healing  
   142–3  
 Global Lower Extremity Amputation  
   Study 34  
 glycaemic control 33, 94–5, 98, 99, 329–30,  
   379, 483  
 glycated haemoglobin (HbA1C) 483  
 glycosylation 129  
 Google 217  
 gout 164–5  
 graft tunnelling, bypass surgery 242  
 Gram stains 56  
 granulocyte colony stimulating factor  
   (G-CSF) 266  
 GRF *see* ground reaction force  
 Grodinsky, Manuel 292  
 gross domestic product (GDP), diabetes cost  
   comparison 202  
 ground reaction force (GRF) 191, 371  
 growth factors, wound healing 444, 450

## h

haemodialysis, EQ-5D score 19  
 haemostasis 295, 353  
 half shoes 131  
 hallux (great toe) amputation 354–5, 367,  
   379, 380  
 hallux (great toe) surgical  
   reconstruction 379–82  
 hallux valgus (bunion) 92, 111, 334, 355,  
   356  
 hammertoes 413  
 hASCs *see* human adipose-derived stems  
   cells  
 HbA1C *see* glycated haemoglobin  
 healer’s medicine 80  
 healing *see* wound healing  
 healthcare costs *see* costs of diabetic foot  
   disease/treatment  
 healthcare priorities, setting of 22–5  
 health outcomes  
   and access to healthcare 25  
   clinical audit of foot care 432–4, 437, 438  
   clinical trial assessment 230–1

- and delayed presentations 52
  - diabetic foot ulcer 7–8
  - Sub-Saharan Africa, diabetes populations 55
  - health-related quality of life (HRQoL) 8, 19
  - health status of patients, DFU impact on 146–7
  - heel ulcers 182, 386, 403
  - hematopoietic stem cells (HSCs) 447
  - hemorrhagic callus, self-examination for 414
  - henna paste 80
  - herbal medicine 80
  - HIF-1 *see* hypoxia-inducible factor 1
  - hindfoot
    - amputation 357, 359
    - realignment arthrodesis 334
  - ‘hip strategy’, gait 192
  - Hispanic Americans, diabetes-related amputation risk 37
  - histology, bone specimen analysis 316–17
  - honey-impregnated dressings 308
  - hospitalization
    - for diabetic foot infection 508
    - for diabetic foot ulcer 4, 5, 7
    - inpatient care 259–64, 427
    - pressure ulcer prevention 262
  - hot foot baths 81
  - hot swollen foot, diagnosis and treatment 475–8
  - hot-water bottles 81
  - HRQoL *see* health-related quality of life
  - HSCs *see* hematopoietic stem cells
  - human adipose-derived stems cells (hASCs) 445, 449, 450
  - humidity data, insoles/soles of footwear 210
  - Hungary 70
  - hydrogel dressings 307
  - hydrotherapy 307
  - hyperbaric oxygen therapy 275
  - hyperglycemia 98, 266, 329, 444, 460
  - hypoxia-inducible factor 1 (HIF-1) 444
- i**
- ICD-9 diagnostic codes 4
  - IDF-WPR Diabetic Foot Care Project 75, 76
  - IDSA *see* Infectious Diseases Society of America
  - imaging
    - DFU diagnosis 481, 482–3
    - future directions 181–3
    - modalities 170–3
    - peripheral arterial disease 496–8
    - see also* computed tomography; magnetic resonance imaging; nuclear imaging; positron emission tomography; radiography; ultrasound
  - imipenem-cilastatin 271
  - imipramine 99
  - incisions, surgical 292–4, 295, 358, 381
  - India 43–5, 57
  - Indian Asians, UK
    - DFU risk 35
    - diabetes-related amputation risk 35, 38
    - diabetic neuropathy rates 38
    - PAD rates 38
  - indirect load transfer, amputation 352
  - induced pluripotent stem (iPS) cells 442
  - infection, foot *see* diabetic foot infection
  - infection tracking, surgery 294
  - infectious disease consultation 296
  - Infectious Diseases Society of America (IDSA)
    - antibiotic treatment 270–1
    - DFI classification 267, 507
  - inpatient care 259–64, 427
    - costs of diabetic foot disease/treatment 21, 260–1
    - foot examination on admission 261–2
    - multidisciplinary foot services 261, 262
    - pressure ulcer prevention 262
  - insensate foot, physical activity
    - recommendations 211–14
    - see also* loss of protective sensation
  - insoles
    - metatarsal pads and bars 132, 400, 402
    - orthotic 355, 399
    - shear-reducing insoles 211
    - smart insoles 212–13, 215, 415
    - temperature and humidity monitoring 210

instability *see* balance, impairment

Integra (skin substitute) 464

integrated care framework 488–9

internal Achilles tendon moment arm 191

internal moment arm length (IntMA) 191

International Working Group of the  
Diabetic Foot (IWGDF) 225,  
226, 266, 273

Internet of Things (IoT) 216–17

interphalangeal joint (IPJ)  
neuropathic ulcer under 381  
surgical reconstruction 379–80, 381,  
386, 388

interventional radiologists 423

IntMA *see* internal moment arm length

intra-arterial digital subtraction  
angiography 498

Ionizing Radiation (Medical Exposures)  
Regulations (IR(ME)R) 153

IoT *see* Internet of Things

IPJ *see* interphalangeal joint

iPS *see* induced pluripotent stem cells

Ipswich Touch Test (ITT) 114

Iraq, diabetic foot disease prevalence  
79, 80

IR(ME)R *see* Ionizing Radiation (Medical  
Exposures) Regulations

irremovable total contact casts (iTCCs) 214

irrigation, surgical 295

ischemia  
BASIL trial 253, 254  
chronic limb-threatening ischemia 235,  
237, 238  
ischemic diabetic foot 470, 481  
neovascularization response 445–6, 447  
neuroischemic ulcers 419, 463, 482  
and surgery outcomes 379

iTCCs *see* irremovable total contact casts

ITT *see* Ipswich Touch Test

Ivory Coast  
health outcomes for diabetes  
population 55  
PAD prevalence 54

IWGDF *see* International Working Group of  
the Diabetic Foot

## j

joint specialist clinics 425–6, 427

joint torque profiles 190

Jones fracture of the fifth metatarsal 159

Jordan  
DFU in 80  
diabetic foot disease prevalence 79

J wire 250, 251

## k

Keller arthroplasty 380, 382

Kenya  
health outcomes for diabetes  
population 55  
PAD prevalence 54  
peripheral neuropathy prevalence 53

keystone design perforator island flaps 465

keystone flaps 465

kidney disease/impairment 18, 44, 110, 254,  
330

K levels (Medicare Functional Classification  
Measure) 365–6

knee abscess 171

knee disarticulation amputation 350,  
351, 361  
prosthetics 371–2

knee-high walkers 130, 131

knee units 373

Kuwait, diabetic foot disease prevalence  
79, 80

Kyoto Foot Meeting Project 75

## l

Laboratory Risk Indicator for Necrotising  
Fasciitis (LRINEC score) 291

laboratory tests 276, 291, 420, 483

laces, footwear 398

large fibre function assessment 92

larval debridement 275, 280, 307, 483

‘last resort’ referral model 204

lateral supramalleolar flaps 465–6

LDA *see* Linear Discrimination Analysis

leadership, diabetic foot clinics 428

lead zirconate titanate (PZT) piezoceramic  
sensors 205



- LEA (lower extremity amputation) *see* amputation
- LEAP *see* Lower Extremity Assessment Project
- Lebanon 80
- leg bypass operations *see* bypass surgery
- lesser metatarsal heads, surgery 383–5
- lesser toes
- amputation 355, 356
  - surgical reconstruction 382–3
- leucocyte scans 277
- leukocytosis 291
- levofloxacin **270, 271**
- LHBs *see* Local Health Boards
- lifestyle, health implications of 81
- lignocaine, intravenous 100
- limb preservation, relative benefit of 241
- Linear Discrimination Analysis (LDA) 449
- linezolid **271, 274**
- Lisfranc fracture dislocation 163, 171
- load transfer, footwear 400
- local flaps, reconstructive surgery 465–6, 468
- Local Health Boards (LHBs) 436
- locking plate fixation, CN midfoot 332
- Loeffler-Ballard incision 292
- loss of protective sensation (LOPS)
- diagnosis 397
  - footwear for patients with 398, 399, 405–7
  - see also* insensate foot
- lower extremity amputation (LEA) *see* amputation
- Lower Extremity Assessment Project (LEAP) 347, 350
- Lower Extremity Threatened Limb Classification System 235, **236**, 238, 243
- LRINEC score (Laboratory Risk Indicator for Necrotising Fasciitis) 291
- m**
- MAC *see* medial artery calcinosis
- maggots (larvae), wound cleaning 275, 280, 307, 483
- magnetic resonance imaging (MRI) 167, 170–2, 177–81, 483
- apparent diffusion coefficient 179–81, 182
  - Charcot foot 174, 177, 178, 179
  - contrast enhancement 179, 498
  - diffusion weighted imaging 179, 180, 181, 182
  - Dixon-based techniques 178–9
  - gadolinium contrast 179, 498
  - intramuscular non-contractile material 189
  - multiplanar imaging 179
  - muscle atrophy, diabetic neuropathy 129
  - osteomyelitis diagnosis 176, 181, 277
  - procedure 178
  - short TI inversion recovery sequence 178
- Malta 5
- Maori people 86
- Marshall Islands 87
- matrix metalloproteinases (MMPs) 143, 309
- MD-CTA *see* multidetector-row computed tomography angiography
- MDFCTs *see* Multidisciplinary Diabetic Foot Care Teams
- MDFS *see* multidisciplinary foot services
- MDROs *see* multidrug-resistant organisms
- ME *see* Middle East
- medial artery calcinosis (MAC) 296, 329
- medial plantar flaps 465–6
- median nerve palsy 97
- medical costs *see* costs of diabetic foot disease/treatment
- Medicare Functional Classification Measure (MFCM) 365–6
- Medicare patients 37
- Meggitt-Wagner wound classification 2, **3**, 6, 434
- mesenchymal stem cells (MSCs) 442, 444, 447, 449, 451
- meta-analyses 227
- METALS *see* Military Extremity Trauma/Amputation Limb Salvage Study
- metatarsal head procedures 379–82
- metatarsal head resection (MHR) 129, 379, 384–5, 386, 388

- metatarsal heads (MTHs), offloading
    - footwear 402
  - metatarsal (MT) pads and bars 400, 402
  - metatarsal osteotomy 383–4
  - metatarsophalangeal joint (MPJ), surgical
    - reconstruction 379–82, 386
  - methicillin-resistant *S. aureus* (MRSA)
    - 269–74, **509**
    - treatment of 273–4
  - Mexican Americans, diabetes-related
    - amputation risk 37
  - MFCM *see* Medicare Functional Classification Measure
  - mHealth (mobile health) 215–16
  - MHR *see* metatarsal head resection
  - microangiopathy 181
  - microbiological control, diabetic foot
    - ulceration 485–7
  - microbiologists 423–4
  - microbiology, diabetic foot infection
    - 268–72, **481**
  - Micronesia 87
  - microprocessor knees 373
  - microsurgery, reconstructive 466–8
  - microvascular complications, DFU risk 110
  - Middle East (ME) 79–83
  - midfoot
    - amputation 357, 358
    - Charcot foot deformity correction 327, 328, 331–3, 335
    - cross-sectional view 293
    - osteomyelitis, surgery 390
  - midfoot ulcers 403
  - Military Extremity Trauma/Amputation
    - Limb Salvage Study (METALS) 348
  - minimal invasive surgery (MIS) 383
  - minor amputation 17, 24, 32, 146
  - MIS *see* minimal invasive surgery
  - MMPs *see* matrix metalloproteinases
  - mobile health (mHealth) 215–16
  - mobile phones 215
    - see also* smartphones
  - moisturizing creams 81
  - monocytes 265, 266, 316
  - monofilament testing 92
  - mononeuropathy (mononeuritis complex) **90**
  - morphine 100
  - mortality
    - amputation 7–8, 20, 31, 201, 239, 459
    - bypass surgery 237
    - diabetic foot ulcer 7–8, 20, 479
    - risk for diabetic patients 6–8, 20
    - Sub-Saharan African diabetic patients 56
  - ‘Morton’s extension’ 355
  - motor neuropathy 110, 129
  - moxifloxacin **270**
  - MPJ *see* metatarsophalangeal joint
  - MRI *see* magnetic resonance imaging
  - MRSA *see* methicillin-resistant *S. aureus*
  - MSCs *see* mesenchymal stem cells
  - MT *see* metatarsal pads and bars
  - MTHs *see* metatarsal heads
  - multidetector-row computed tomography
    - angiography (MD-CTA) 497
  - multidisciplinary approach, reconstructive
    - surgery 460, 461
  - Multidisciplinary Diabetic Foot Care Teams (MDFCTs) 47–8, 49
  - multidisciplinary foot services (MDFS) 261, 262, 488
  - multidisciplinary teams, diabetic foot
    - clinics 425–6
  - multidisciplinary treatment, diabetic foot
    - ulcer 10
  - multidisciplinary vascular radiology
    - meetings 426–7
  - multidrug-resistant organisms (MDROs) 269
  - muscle denervation, neuropathic 178
  - muscle forces, and gait 188–90
  - muscle strength
    - improvement in 197–8
    - tests 188–9
  - muscular weakness and wasting 92, 96, 110, 129, 188
  - musculoskeletal examination 290–1
- n**
- NaDIA *see* National Diabetes Inpatient Audit
  - nails *see* toenails

- National Diabetes Audit (NDA) 435
- National Diabetes Foot Care Audit of  
     England and Wales (NDFA) 25, 303,  
     425, 435–9  
     clinical outcomes 437, 438  
     dataset limitations 438  
     design of 436–7  
     findings of (2014–17) 437–9  
     foot care pathway 436  
     structural audit 438  
     variation between service providers 438
- National Diabetes Inpatient Audit  
     (NaDIA) 260, 261, 262
- National Health Service (NHS), clinical audit  
     of foot care 435
- National Inpatient Sample (NIS), US 4
- National Institute for Health and Care  
     Excellence (NICE)  
     diabetic foot care framework 23  
     EQ-5D instrument 19  
     inpatient care guidelines 261
- Native Americans, diabetes-related  
     amputation risk 35–7
- navicular fracture 158, 159
- NDA *see* National Diabetes Audit
- NDFA *see* National Diabetes Foot Care Audit  
     of England and Wales
- necrosis 419, 442, 469
- necrotising fasciitis 162, 291
- negative pressure wound therapy  
     (NPWT) 297, 308–9, 483
- neovascularization 445–7, 449
- nephrogenic systemic fibrosis (NSF) 498
- nephrotoxicity 254
- nerve entrapment 97
- nerve transection 354
- NeuRODiab *see* Society for Diabetic  
     Neuropathy
- neuroischaemia 483
- neuroischemic ulcers 53, 419, 463, 482
- neurological assessment 113–14, 290
- neuropathic pain 91, 98–101  
     not responding to pharmacological  
     treatment 100  
     treatment algorithm 100, 101
- neuropathic ulcers 463
- neuropathy *see* diabetic neuropathy
- Neuropathy Disability Score (NDS) 113
- Neuropathy and Foot-Ulcer-Specific Quality  
     of Life instrument (NeuroQoL) 147
- neuropeptides 315
- New Zealand (NZ)  
     amputation rates 86  
     DFU prevalence 87  
     South Asian diabetes-related  
     amputation 38
- NICE *see* National Institute for Health and  
     Care Excellence
- Nigeria  
     health outcomes for diabetes  
     population 55  
     PAD prevalence 54  
     peripheral neuropathy prevalence 53
- NIS *see* National Inpatient Sample
- non-healing ulcers 449  
     *see also* reconstructive surgery
- non-invasive bedside testing, PAD  
     diagnosis 494
- Norfolk QoL-Diabetic Neuropathy Scale 68
- Norway, clinical audit of foot care 439
- Novartis 217
- NPWT *see* negative pressure wound therapy
- NSF *see* nephrogenic systemic fibrosis
- nuclear imaging, osteomyelitis  
     diagnosis 277
- nurses 422
- nutrition 460
- NZ *see* New Zealand
- O**
- occupational therapists 424
- oedema  
     DFU risk 110  
     fsT2W imaging 178  
     MRI scans 174, 180, 182  
     radiographs 172  
     treatment 487
- offloading 130–2, 133, 298  
     adherence to 143–4, 145, 148, 214–15  
     Charcot foot 319–20

- offloading (*cont'd*)
    - smart technology 203–4
    - surgical offloading 378–9, 385–6, 413
    - therapeutic footwear/orthoses 401–4, 412
  - OPAT *see* outpatient parenteral antibiotic therapy
  - open bypass surgery *see* bypass surgery
  - opiates, neuropathic pain management 100
  - orthopaedic clinics 426
  - orthopaedic surgeons 423, 426
  - orthotics 367–8, 399–400, 405
    - ankle foot orthosis 357
    - design optimization 403
    - in-shoe plantar pressure 403
    - insoles 355, 399
  - orthotists 422
  - osseous structures, surgical reconstruction 298–9
  - ossicle, accessory 166
  - osteoarthropathy 178
  - osteoclast activation, Charcot foot 316
  - osteoclastogenesis 330
  - osteolysis 317
  - osteomyelitis 170, 275–81, 482, 483
    - amputation 388
    - antibiotic versus surgical treatment **512**
    - characteristics of **277**
    - CT scans 176
    - diagnosis 276–8
      - bone biopsy 278
      - clinical findings 276
      - imaging studies 276–8
      - laboratory tests 276
      - probe-to-bone test 276
      - strategies 278, **279**
    - forefoot osteomyelitis, surgery 388–90
    - incidence of 275
    - infection identification 480
    - management of **279**
    - midfoot osteomyelitis, surgery 390
    - MRI scans 167, 176, 181
    - positron emission tomography 278
    - radiographs 155, 157, 160–2, 174, 276–7
    - rear foot osteomyelitis, surgery 390–1
    - serial radiography 156
    - treatment 275–6, 278–81, 509, **512**
      - adjunctive therapy 280
      - antibiotic treatment 278, 280–1
      - challenges of 278
      - duration of 280–1
      - surgery 280, 377, 387–91
  - osteopenia 163
  - osteoprotegerin (OPG) 316, 318
  - osteotomy, metatarsal 383–4
  - outcomes *see* health outcomes
  - outpatient care, costs of diabetic foot care, England 21
  - outpatient parenteral antibiotic therapy (OPAT) 427
  - over-the-counter medicines 80
  - oximetry tests 237, 496
  - oxycodone 100
  - oxygen tests, transcutaneous 248
  - oxygen, topical, wound healing 308
- p**
- Pacific region 75–7, 86–7
  - PACS *see* picture archive and communication system
  - PAD *see* peripheral arterial disease
  - pain
    - abdominal pain 96
    - loss of 120
    - neuropathic pain 91, 94–5, 98–101
    - purpose of 108
  - pain clinics 100
  - ‘painful–painless leg’ 108
  - Pakistan 47–9
  - Pakistan Working Group on the Diabetic Foot (PWGDF) 48
  - palliative wound care 239
  - palsies 96, 97
  - pan metatarsal head resection 385, 386
  - Papua New Guinea 86, 87
  - patellar tendon bearing sockets 369
  - patient centred outcomes 8–9
  - patient education
    - Brazil 64
    - Cochrane review 487
    - efficacy of 139–40

- in India 57
- remission maintenance 413–14
- Romania 68–9
- Saudi Arabia 81–2
- smart technology 214–15
- Sub-Saharan Africa 56–8
- patient health status, DFU impact on 146–7
- Patient Interpretation of Neuropathy (PIN)
  - questionnaire 142
- patient perceptions
  - of balance impairment/unsteadiness 144–5, 148
  - of DFU risk 141–2
- PCR *see* polymerase chain reaction
- pedal access technique, endovascular
  - revascularization 251
- pedal fracture, athletes 158
- PEDIS classification 267, 268, 434, 507
- PEDIS Grade 2 (mild) infections 273–4
- PEDIS Grade 3 (moderate) infections 274
- PEDIS Grade 4 (severe) infections 274–5
- peer counselling 354
- pencillin 273
- perforator flaps 465, 467–8, 469, 470
- peripheral arterial disease (PAD) 6, 247–57, 493–504
  - amputation risk factor 33
  - ankle brachial index 494–5
  - ankle Doppler signals 495
  - assessment for 329
  - bypass surgery 235–45
  - clinical examination 494
  - clinical significance of 434
  - clinical trial assessment 228
  - colour Doppler ultrasound 496–7
  - contrast-enhanced magnetic resonance angiography 498
  - definition of 434, 493
  - and DFU pathogenesis 106–7
  - diagnosis 248–9, 494–6
  - endovascular revascularization 250–5
  - history 494
  - identification of 235–7
  - imaging 496–8
  - incidence of 106, 247–8
  - Indian Asians, UK 38
  - intra-arterial digital subtraction angiography 498
  - management of 250
  - multidetector-row computed tomography angiography 497
  - non-invasive bedside testing 494
  - in Pakistan 47–8
  - pathophysiology of 248
  - pulse oximetry 496
  - skin perfusion pressure 496
  - in Sub-Saharan Africa 51, 53–4
  - testing for 481–2
  - toe brachial index 495
  - toe pressure measurement 495
  - transcutaneous oxygen tension measurement 495–6
  - ultrasound scans 175
  - vascular evaluation 494–6
    - algorithms 498, 499, 500
  - vascular imaging 496–8
    - in Western Pacific region 76
- peripherally inserted central catheters (PICCs) 427
- peripheral neuropathy (PN) *see* diabetic neuropathy
- peripheral sympathetic autonomic neuropathy 108–9
- peripheral vascular disease (PVD)
  - bypass surgery 235–45
  - in India 44
  - radiography 157
- Peru, DFU and amputation prevention 10
- PET *see* positron emission tomography
- phalanges, bone resorption 164
- phantom-limb pain 353–4
- pharmacists 424
- phlebotomy service 422
- photographs, clinical 166
- physical activity
  - and DFU risk 148
  - and diabetic neuropathy 196–8
  - harmful activities 213
  - and healing 145, 214
  - levels of 213

- physical activity (*cont'd*)
  - management of 211–14
  - recommendations for diabetes persons 211–14
  - and smart technology 211–14
  - weight-bearing exercise 196, 197
- physiological stress, and DFU healing 143
- physiotherapists 424
- physiotherapy 96
- PICC lines 427
- picture archive and communication system (PACS) 166
- piezoceramic sensors 205
- PIN *see* Patient Interpretation of Neuropathy
- pinprick test **113**
- pin suspension 370
- piperacillin-tazobactam **271, 274**
- placental membrane, wound closure 297
- plain radiography *see* radiography
- plantar area at risk, offloading 403–4
- plantar electrical stimulation 217–18
- plantar foot, compartments of 292, 293
- plantar plating, Charcot foot 332
- plantar pressure, and diabetic foot ulcer 119–20
- plantar pressure elevation
  - measurement of 126, 127–8, 132
  - mechanisms of 128–30
  - peak pressure threshold 133
- plantar pressure measurement 113, 114, 115, 125–8, 132, 204–8, 212–13, 401–3
  - concept of pressure 125–6
  - orthoses 405
  - peak pressure threshold 127
- plantar temperature measurement/monitoring 204, 206–10, 211, 319, 415
- plastic clinics 427
- plastic surgeons 423
  - see also* reconstructive surgery
- plastic surgery consultation 296
- platelet-rich plasma (PRP) 450
- plexopathy 95–6
- PMN *see* polymorphonuclear cells
- pneumatic knee units 373
- PN (peripheral neuropathy) *see* diabetic neuropathy
- podiatrists 421–2
- podiatry 69, 488
- Podometrics mat 207
- polymerase chain reaction (PCR) 448
- polymorphonuclear cells (PMN) 265, 266
- polytetrafluoroethylene (PTFE) prosthetic conduit 242
- popliteal artery revascularization 253
- populations
  - clinical audit of foot care 434
  - clinical trials 227–8
- porcine products, wound healing 464
- positron emission tomography (PET) 153–4, 278
- postural instability *see* balance, impairment
- prealbumin 460
- pregabalin 99
- preoperative care 378–9
- prescription shoes *see* footwear
- presentation delays 419
- pressure assessment/perception *see* foot pressure assessment/perception
- pressuremat **112**
- pressure palsies 97
- PressureStat Foot Print 114, 115
- pressure ulcers, prevention of 262
- prevention programmes *see* patient education
- primary care, costs of diabetic foot care, England 21
- probe-to-bone test, osteomyelitis
  - diagnosis 276
- progenitor cells 444–5, 446, 447
- propeller flaps 465, 466, 469
- prophylactic surgery 377–86
- prostate cancer 18, 19
- prosthetics 365–76
  - ankle-foot components 371–3
  - foot amputation 366–8
  - foot orthotics 367–8
  - K levels 365–6
  - knee disarticulation amputation 371–2
  - knee units 373
  - lower limb amputation 365–6

- Medicare Functional Classification Measure 365–6
  - metabolic cost of walking with a prosthesis 348–9
  - shanks 370
  - sockets 350–2, 369, 372–3
  - suspension 370, 372–3
  - transfemoral amputation 372
  - transtibial amputation 368–70
  - transtibial sockets 369
  - proximal foot amputation, prosthetics 368
  - proximal motor neuropathy 95–6
  - PRP *see* platelet-rich plasma
  - Pseudomonas aeruginosa* 269, **271**, **509**
  - psychiatrists 424
  - psychological factors 139–51
    - DFU development 139–42
    - DFU healing 142–5
    - quality of life impacts 146–8
  - PTFE *see* polytetrafluoroethylene prosthetic conduit
  - publications, DFU-related 225, 226
  - pulsed radio frequency energy, wound healing efficacy 218
  - pulse oximetry 496
  - ‘Putting Feet First’ campaign 261
  - PVD *see* peripheral vascular disease
  - PWGDF *see* Pakistan Working Group on the Diabetic Foot
  - pyomyositis, ultrasound scans 175
  - PZT *see* lead zirconate titanate piezoceramic sensors
- q**
- QALYs *see* quality-adjusted life years
  - QoL *see* quality of life
  - QST *see* quantitative sensory testing
  - quality-adjusted life years (QALYs) 19, 23–4
  - quality of care 23
  - quality of life (QoL) 19
    - amputation impact 347, 348
    - DFI impact on 289
    - DFU impact on 146–8
    - diabetic neuropathy patients 68
    - measurement of 147–8
    - patient-reported outcome measures 8
  - quantitative sensory testing (QST) 114
  - questionnaires
    - Diabetic Foot Ulcer Scale 147
    - foot care pathway 436
    - Patient Interpretation of Neuropathy 142
- r**
- race *see* ethnicity
  - radial nerve palsy 97
  - radiculopathy, truncal **90**, 96
  - radio frequency energy, wound healing efficacy 218
  - radiography 153–68, 170, 173–4, **481**, 482–3
    - Charcot foot 156, 162–4, 172, 173, 174, 319, 326, 327–8, 333
    - clinical information 166
    - computerized radiography 154, 155
    - DFI evaluation 291
    - direct digital radiography 154, 155
    - foot deformities 158
    - foreign body identification 174
    - fractures 158–60
    - gas, in soft tissues 294
    - gout 164–5
    - image resolution 154–5
    - justification for 153
    - limitations of 154
    - Lisfranc dislocation 171
    - normal variants 165–6
    - osteomyelitis 155, 157, 160–2, 174, 276–7
    - patient preparation 156
    - peripheral vascular disease 157
    - photographic correlation 166
    - projections 156
    - radiation risk 153
    - serial radiography 156–7
    - traumatic ulcer 117
    - ulceration predictors 327–8
    - vasculopathy 157
  - radiologists 423
  - randomized controlled trials (RCTs) 226–7, 304



- RANKL *see* receptor activator of nuclear factor kappa-B ligand
- ray resection 355–7, 367
- RCTs *see* randomized controlled trials
- RCWs *see* removable cast walkers
- realignment arthrodesis 331–4, 333, 337
- rear foot osteomyelitis, surgery 390–1
- receptor activator of nuclear factor kappa-B ligand (RANKL) 316, 317, 318, 320
- reconstructive surgery 459–73
- and amputation 468
  - care spectrum 460, 461
  - debridement 462–3
  - elevator approach 461–2, 466
  - flap reconstruction 463, 465–8
    - failures 468
    - flap survival rate 468
    - free flaps 466–8, 469
    - goals of 467
    - local flaps 465–6, 468
  - indications for surgery 466–7
  - microsurgery 466–8
  - multidisciplinary approach 460, 461
  - reconstruction algorithms 461–2
  - skin grafts/substitutes 464–5
  - step-ladder approach 461, 466
  - supermicrosurgery 468, 469
  - survival rate 468
  - vascular status evaluation/
    - enhancement 463–4
  - wound-closure ladder 461
- recurrence of DFU 5, 6, 133, 204, 378, 411, 435
- referral pathway 488–9
- regenerative medicine 441–57
- advances in 449–51
  - stem cells 441–4, 446–51
    - functional heterogeneity of 448–9
  - vascular dysfunction 445–7
  - wound healing 444–5
- region perspectives *see* country/region perspectives
- Regulations, Ionizing Radiation (Medical Exposures) 153
- religious practices 81
- remission 411–17
- components of 412
  - footwear 412
  - monitoring technology 415
  - offloading footwear 412
  - patient education 413–14
  - self-care behaviours/practices 414
  - surgical offloading 413
  - wearable technology 415
- removable cast walkers (RCWs) 131, 145, 214
- renal disease/impairment 18, 44, 110, 254, 330
- resistance exercise training 196–7, 198
- revascularization *see* bypass surgery; endovascular revascularization
- reverse sural flaps 465–6
- rheumatoid arthritis 126
- risk assessment
- amputation 32–3
  - bypass surgery 237–9
  - DFU risk 111–15, 204–11
  - of diabetic foot 93
  - screening techniques for ‘at-risk’ foot 112
- ‘rocker bottom’ foot 128–9, 330–1
- rocker shoes 131, 368, 400, 401
- roller shoes 400, 401
- Romania 67–9
- Rothman model, DFU causation 116
- Russian Federation 9, 70–1
- Rydel Seiffer tuning fork 44
- S**
- SA *see* Saudi Arabia
- S(AD)SAD wound classification 2, 3, 6
- Samoa 87
- sampling techniques 269, 295, 480–1
- San Antonio wound classification 9–10
- Sanders and Frykberg Anatomic Classification for Charcot Osteoarthropathy 327
- Saudi Arabia (SA) 79, 80
- Saving the Diabetic Foot Project 61, 62
- SbS *see* Step by Step foot projects
- SCIP *see* superficial circumflex iliac artery flap



- Scotland  
     DFU incidence 18  
     Diabetes Audit and Research in Tayside  
         Scotland study 106  
 Seattle Diabetic Foot Study 2  
 sedentary lifestyle 81  
 Seldinger technique, endovascular  
     revascularization 250, 251  
 selective serotonin and norepinephrine  
     reuptake inhibitors (SSNRIs)  
     99–100, 101  
 self-care behaviours/practices  
     amputation risk 6  
     and depression 140–1  
     DFU risk 6, 141–2  
     poor self-care 147–8  
     remission maintenance 414  
 Sensoria Socks 205  
 sensorimotor neuropathy, and DFU  
     pathogenesis 108  
 sensor technologies 217  
 sensory loss, diabetic neuropathy 91, 95,  
     108, 109, 120  
 SENSUS (wearable electrical stimulation  
     system) 217, 218  
 sepsis 55, 267  
 serial radiography 156–7  
 serotonin and norepinephrine reuptake  
     inhibitors (SNRIs) 99–100, 101  
 sesamoid bones, radiography 156, 165  
 sesamoidectomy 382, 386  
 sex of patient, and DFU risk 109  
 SF-36 physical functioning scale  
     146, 147  
 SFA *see* superficial femoral artery  
 shanks, prosthetics 370  
 sharp debridement 306–7  
 shear stress  
     plantar foot ulcer 128  
     thermal stress response assessment  
     210–11  
 shoelaces, tightness of 211  
 shoes *see* footwear  
 Shore A scale 399  
 Short Form (36) Health Survey 146, 147  
 short TI inversion recovery (STIR)  
     sequence 178  
 Silfverskiöld test 299  
 SINBAD classification system  
     434, **437**, 482  
 Single-Axis Foot 371  
 single-cell transcriptional analysis 448  
 single photon emission computed  
     tomography (SPECT) 172–3  
 Siren Socks 209–10  
 SIRS *see* systemic inflammatory response  
     syndrome  
 Sistema Único de Saúde (SUS) 61  
 Site, Ischaemia, Neuropathy, Bacterial  
     Infection, Area and Depth (SINBAD)  
     classification 434, **437**, 482  
 Size (Area, Depth), Sepsis, Arteriopathy,  
     Denervation (S(AD)SAD) wound  
     classification 2, 3, 6  
 skin examination, DFI evaluation 290  
 skin grafts/substitutes 308, 464–5  
 skin perfusion pressure (SPP) 237, 496  
 skin temperature measurement *see* plantar  
     temperature measurement/  
     monitoring  
 sleeve suspension 370  
 slip-on shoes 398  
 Slovak Republic 70  
 SM *see* surface marker profiles  
 smartphones 205, 212  
 SmartSox 207–9, 208, 415  
 smart technology 201–24  
     DFU prevention 214–15  
     DFU risk assessment 204–11  
     footwear-related offloading treatment  
     203–4  
     Internet of Things 216–17  
     offloading treatment 203–4  
     patient education 214–15  
     physical activity management 211–14  
     remission maintenance 415  
     therapy in the home 217–18  
     wearable technology 203–4, 216–18, 415  
 smartwatches 205, 212–13  
 smoking 33, 143, 487

- SNRIs *see* serotonin and norepinephrine reuptake inhibitors
- Society for Diabetic Neuropathy (NeuroDiab) 69
- socio-economic factors 34, 146
- sockets, prosthetics 369, 372–3
- socks, smart technology 205, 207–10
- soft tissue envelope, amputation surgery 350, 352, 353, 357
- soft tissues, gas in 291, 294
- soft tissue/tendon balancing 299
- soft tissue ulceration 162
- solid ankle cushioned heel (SACH) 371
- Solomon Islands 87
- Somerset Clinical Commissioning Group, foot care service 24
- South Africa  
     PAD prevalence 54  
     peripheral neuropathy prevalence 53
- South Asians, UK *see* Indian Asians, UK
- SPECT *see* single photon emission computed tomography
- split thickness skin grafting (STSG) 297–8
- SPP *see* skin perfusion pressure
- SSA *see* Sub-Saharan Africa
- SSNRIs *see* selective serotonin and norepinephrine reuptake inhibitors
- stair-walking, and balance/fall risk 193, 195, 407
- standing, and DFU risk 213
- Staphylococcus aureus* 269, 270, 276, 509
- stem cells 441–51  
     adipose-derived stems cells 441, 443, 444, 449–50  
     bone marrow-derived stem cells 451  
     embryonic stem cells 444  
     functional heterogeneity of 448–9  
     hematopoietic stem cells 447  
     human adipose-derived stems cells 445, 449, 450  
     mesenchymal stem cells 442, 444, 447, 449, 451
- stents 253
- Step by Step (SbS) foot projects 48, 57, 62, 64
- STIR *see* short TI inversion recovery sequence
- stress, and DFU healing 143
- stroke 18, 20
- stromal vascular fraction (SVF) 444
- STSG *see* split thickness skin grafting
- subcutaneous tunnelling, bypass surgery 242
- Sub-Saharan Africa (SSA) 51–60  
     DFI in 55–6  
     DFU in 51, 52, 54–5  
     diabetes incidence and prevalence 51  
     education programmes 56–8  
     health outcomes for diabetes populations 55  
     mortality rates in diabetic patients 56  
     PAD in 53–4  
     peripheral neuropathy in 52–3  
     prevention programmes 56–8
- suction sockets 369
- suction suspension 370
- Sudan  
     health outcomes for diabetes population 55  
     PAD prevalence 54  
     peripheral neuropathy prevalence 53
- superconstruct fixation 332, 335
- superficial circumflex iliac artery (SCIP) flap 470
- superficial femoral artery (SFA) 251, 253
- supermicrosurgery 468, 469
- supracondylar/suprapatellar sockets 369
- surface marker (SM) profiles 447
- surgery 289–302, 377–95, 459–73  
     Achilles tendon lengthening 129, 299, 336, 337, 357, 385–6, 404, 413  
     classification of 377  
     clinical trial assessment 231  
     deformity correction 413  
     DFU prevention 378  
     diabetic foot infection 289–302  
     fifth metatarsal head resection 384, 385  
     first metatarsal head procedures 379–82  
     hallux (great toe) procedures 379–82  
     incision techniques 292–4, 381  
     interphalangeal joint reconstruction 379–80, 386, 388

- lesser metatarsal heads 383–5  
 lesser toes 382–3  
 metatarsal head procedures 379–85  
 metatarsal head resection 384–5, 386, 388  
 metatarsal osteotomy 383–4  
 metatarsophalangeal joint  
     reconstruction 386  
 microsurgery, reconstructive 466–8  
 minimal invasive surgery 383  
 osteomyelitis treatment 280, 377, 387–91  
     conservative approach 387–8  
     forefoot osteomyelitis 388–90  
     midfoot osteomyelitis 390  
     rear foot osteomyelitis 390–1  
 pan metatarsal head resection 385, 386  
 plantar foot ulcers 132, 133  
 post-operative evaluation 176–7  
 preoperative care 378–9  
 prophylactic surgery 377–86  
 reconstructive surgery 459–73  
 supermicrosurgery 468, 469  
 surgical offloading 378–9, 385–6, 413  
 toe reconstruction 382–3  
 vascular surgery consultation/  
     evaluation 460  
 versus footwear modification 404  
*see also* amputation; bypass surgery;  
     Charcot neuroarthropathy (Charcot  
     foot), surgical reconstruction  
 SurroSense Rx 212–13, 415  
 SUS *see* Sistema Único de Saúde  
 suspension, prosthetics 370, 372–3  
 SVF *see* stromal vascular fraction  
 swab specimens 269  
 sweat indicator test 114  
 swollen foot, diagnosis and treatment  
     475–8  
 Syme's ankle disarticulation amputation  
     357, 358–9, 360  
 symmetrical neuropathies  
     acute painful neuropathies 94–5  
     distal symmetrical neuropathy 91–3  
 systematic reviews 227, 273  
 systemic inflammatory response syndrome  
     (SIRS) 267, 291
- t**  
 T1 weighted imaging 178, 179  
 TAL *see* tendon Achilles lengthening  
 talectomy 334  
 talus, tibiototalcalcaneal arthrodesis 334  
 Tanzania  
     DFU in 54–5  
     health outcomes for diabetes  
         population 55  
     PAD prevalence 54  
     peripheral neuropathy prevalence 53  
     Step by Step foot projects 57  
 TASC *see* TransAtlantic Inter-Society  
     Consensus II guidelines  
 TBI *see* toe brachial index  
 TCA *see* tricyclic antidepressants  
 TCCs *see* total contact casts  
 TcPO<sub>2</sub> *see* transcutaneous oxygen tension  
     measurement  
 Technetium Sulphur colloid imaging 177  
 technology *see* smart technology  
 temperature perception, dorsal foot  
     113, 114  
 tendinopathy, ultrasound scans 175  
 tendon Achilles lengthening (TAL) 129,  
     299, 336, 337, 357, 385–6, 404, 413  
 tenosynovitis 175, 181  
 tenotomy 132, 133, 389  
 TENS *see* transcutaneous electrical nerve  
     stimulation  
 'terminal Syme's amputation' 354  
 Texas University wound classification 2, 3,  
     6, 291, 434  
 textile pressure sensors 205  
 TG *see* triglyceride  
 Thailand 10, 75  
 therapeutic footwear *see* footwear  
 therapies, clinical trials, assessment  
     of 225–34  
 thermal stress response (TSR) 210–11  
 thermography tools 206–7  
 thermometry 319, 415  
 tibial disease 252  
 tibial revascularization 253–4  
 tibiototalcalcaneal arthrodesis 334

- tigecycline **271**
  - time trends data, amputation 34–5
  - Timor-Leste 87
  - Tip therm 44
  - tissue management, amputation 353–4
  - tissue regeneration 446, 447
  - tissue sampling 269, 295, 480–1
  - tissue viability, colour guide 294
  - TMA *see* transmetatarsal amputation
  - TNF *see* tumor necrosis factor
  - toe brachial index (TBI) 329, 495
  - toe filler 355, 357, 367
  - toenails
    - fungal infection of 55
    - trimming of 81
  - toe pressure
    - PAD diagnosis 248, 495
    - tests 237
  - toes
    - clawing of 92, 119, 128, 413
    - surgical reconstruction 382–3
  - toe tips, plantar pressure elevation 128
  - toe ulcers 132, 382, 404
  - Tonga 87
  - topical collagenases, wound cleaning 307
  - total contact casts (TCCs) 130, 131, 145, 214, 319, 320, 385–6, 485
  - total contact sockets 369
  - touch perception 92
  - tourniquets, use of 353
  - Train the Foot Trainer (TtFT) Project 57–8
  - training courses, Step by Step foot project, Brazil 64
    - see also* patient education
  - tramadol 100
  - TransAtlantic Inter-Society Consensus (TASC) II guidelines 250
  - transcriptional analyses 448
  - transcutaneous electrical nerve stimulation (TENS) 100, 218
  - transcutaneous oxygen tension measurement (TcPO<sub>2</sub>) 495–6
  - transfemoral amputation 352, 361–2
    - prosthetics 372
  - Translating Research Into Action for Diabetes (TRIAD) 4
  - transmetatarsal amputation (TMA), orthotics 367–8
  - transplantation patients, DFU risk 111
  - transtibial amputation 299–300, 337, 352, 359–61
    - prosthetics 368–70
  - transtibial sockets 369
  - trapped nerves 97
  - trauma
    - and DFU 106, 117, 127
    - inflammatory response in Charcot foot 315–16
    - nail trimming 81
  - treatment costs *see* costs of diabetic foot disease/treatment
  - TRIAD *see* Translating Research Into Action for Diabetes
  - tricyclic antidepressants (TCA) 99, 101
  - triglyceride (TG) levels, as diabetes-related amputation risk factor 33
  - trimethoprim **270**
  - truncal radiculopathy **90**, 96
  - TSR *see* thermal stress response
  - T-style anastomosis 467
  - TtFT *see* Train the Foot Trainer Project
  - tumor necrosis factor (TNF) 317
  - tuning forks, vibration perception 44, 92, 113
  - type 1 diabetes 32
    - and amputation rates 35
    - EURODIAB Prospective Complications Study 89
    - neuropathy 314
  - type 2 diabetes 32
    - and amputation rates 35–6
    - neuropathy 314
    - progenitor cell depletion 445
    - in Russian Federation 70
- U**
- UAE *see* United Arab Emirates
  - Uganda, PAD prevalence **54**
  - UK *see* United Kingdom

- UKPDS *see* United Kingdom Prospective Diabetes Study
- ulcer, foot *see* diabetic foot ulcer
- ulnar nerve entrapment 97
- ultrasound (US) 170, 175
- bypass surgery follow-up 243
  - Duplex ultrasound 423, 496–7
  - endovascular revascularization 250
- United Arab Emirates (UAE), diabetic foot disease prevalence 79, 80
- United Kingdom Prospective Diabetes Study (UKPDS) 107
- United Kingdom (UK)
- amputation in 34, 35, 479
  - ethnic differences 37
  - costs of diabetic foot disease/ treatment 225
  - Diabetes UK 261
  - financial cost of DFU 9, 10
  - Indian Asians, diabetes-related amputation risk 35, 38
  - inpatient care 259–64
  - National Diabetic Foot Audit 425
  - see also* England; Scotland
- United States (US)
- African Americans, diabetes-related amputation risk 37
  - amputation incidence/rates 34, 365, 479
  - DFU incidence 441, 459
  - diabetes incidence 169, 441
  - financial cost of diabetic foot disease/ treatment 9, 20–2, 170, 225
  - Hispanic Americans, diabetes-related amputation risk 37
  - hospitalizations for diabetic foot disease 4, 5, 260
  - National Inpatient Sample 4
  - Native Americans, diabetes-related amputation risk 35–7
- unsteadiness
- diabetic neuropathy 109, 144–5
  - during gait 195–6
  - patient perceptions of 148
  - therapeutic footwear 407
- US *see* ultrasound; United States
- V**
- vacuum-assisted wound closure device (VAC) 353
- vacuum suspension 370
- valgus deformities *see* hallux valgus (bunion)
- vancomycin 271, 272
- Vanuatu 87
- variation in health care 431–2, 438
- varus deformities 334
- vascular assessment 114, 463–4, 494–6
- algorithms 498, 499, 500
- vascular clinics 426
- vascular control, diabetic foot ulceration 483–4
- vascular dysfunction 445–7
- vascular examination, DFI evaluation 290
- vascular scientists 423
- vascular surgeons 423, 426
- vascular surgery consultation/evaluation 295–6, 460
- vasculogenesis 446, 450
- vasculopathy, radiography 157
- vasodilatation 266
- veins, bypass surgery 240–2
- velcro closure, footwear 398
- vibration perception 92, 112, 113, 114
- Vibratip 114
- Vitamin D deficiency 330
- W**
- Wagner wound classification 2, 3, 6, 434
- Wales, National Diabetes Foot Care Audit 25, 303, 435–9
- walkers *see* cast walkers
- walking *see* gait
- Walking Sense 205
- Waterlow Score 262
- WBC *see* white blood cell count
- wearable technologies 203–4, 216–18, 415
- see also* footwear
- weight-bearing activity/exercise 196, 197, 348
- Western Pacific region (WPR) 75–6
- white blood cell (WBC) count 176, 177, 483
- Wifi *see* Wound, Ischemia, and foot Infection classification system

wound care/healing 306, 308–9, 483  
 antiseptics 307  
 app 215–16  
 bioengineered products 464  
 clinical audit of foot care 434–5  
 clinical trial assessment 231  
 delays in healing **305**  
 dressings 303–11  
 growth factors 444, 450  
 healing time 2, 303, **305**  
 hospital readmission 239  
 impairment of 444–5  
 palliative care 239  
 and physical activity 214  
 post-surgery 242, 243  
 pulsed radio frequency energy 218  
 reconstructive surgery 461  
 regenerative medicine 444–5  
*see also* debridement

wound classification systems 2–3, 6, 9–10,  
 235, **236**, 238, 243, 268, 291, 434  
 wound closure techniques, surgery 296–8  
 Wound, Ischemia, and Foot Infection (WIFI)  
 classification system 235, **236**, 238,  
 243, 268  
 wound management, amputation  
 surgery 353  
 wound types 463  
 WPR *see* Western Pacific region

## X

xenograft 464  
 X-rays *see* radiography

## Z

Zambia  
 PAD prevalence **54**  
 peripheral neuropathy prevalence **53**